10x Genomics, Inc. (TXG)
NASDAQ: TXG · Real-Time Price · USD
69.86
-2.53 (-3.49%)
At close: Oct 16, 2026, 4:00 PM EDT
69.46
-0.40 (-0.57%)
After-hours: Oct 16, 2026, 7:34 PM EDT
10x Genomics Stock Forecast
Stock Price Forecast
According to 19 analysts polled by S&P Global, 10x Genomics stock has a consensus rating of "Buy" and an average price target of $77. The average 1-year stock price forecast is 10.22% higher than the current stock price, while the lowest is $50 (-28.43%) and the highest is $110 (+57.46%).
Price Target: $77 (+10.22%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for 10x Genomics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 6 | 6 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 10 | 10 | 10 | 10 | 12 | 12 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 16 | 16 | 19 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Hold Maintains $47 → $70 | Hold | Maintains | $47 → $70 | +0.20% | Oct 13, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Reiterates $40 → $70 | Hold | Reiterates | $40 → $70 | +0.20% | Oct 12, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $60 → $100 | Buy | Maintains | $60 → $100 | +43.14% | Oct 12, 2026 |
| Bank of America Securities | Bank of America Securities | Hold Maintains $50 → $80 | Hold | Maintains | $50 → $80 | +14.51% | Oct 9, 2026 |
| Barclays | Barclays | Buy Maintains $52 → $110 | Buy | Maintains | $52 → $110 | +57.46% | Oct 7, 2026 |
Financial Forecast
Revenue This Year
620.66M
from 642.82M
Decreased by -3.45%
Revenue Next Year
683.56M
from 620.66M
Increased by 10.13%
EPS This Year
0.04
from 0.12
Decreased by -70.21%
EPS Next Year
0.08
from 0.04
Increased by 109.08%
EPS and Forward PE are based on non-GAAP adjusted numbers.